CLASP1

Summary

CLASP1 (cytoplasmic linker associated protein 1, HGNC:17088) is a protein-coding gene on chromosome 2q14.2-q14.3, encoding CLIP-associating protein 1 (Q7Z460). Microtubule plus-end tracking protein that promotes the stabilization of dynamic microtubules.

CLASPs, such as CLASP1, are nonmotor microtubule-associated proteins that interact with CLIPs (e.g., CLIP170; MIM 179838). CLASP1 is involved in the regulation of microtubule dynamics at the kinetochore and throughout the spindle (Maiato et al., 2003 [PubMed 12837247]).

Source: NCBI Gene 23332 — RefSeq curated summary.

At a glance

• Gene–disease (curated): focal epilepsy (Limited, GenCC) — +1 more curated relationship
• GWAS associations: 9
• Clinical variants (ClinVar): 403 total — 10 pathogenic, 9 likely-pathogenic
• Phenotypes (HPO): 19
• Druggable target: yes
• Dosage sensitivity (ClinGen): haploinsufficiency no evidence, triplosensitivity no evidence
• MANE Select transcript: NM_001395891

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17088
Approved symbol	CLASP1
Name	cytoplasmic linker associated protein 1
Location	2q14.2-q14.3
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0622, MAST1
Ensembl gene	ENSG00000074054
Ensembl biotype	protein_coding
OMIM	605852
Entrez	23332

Gene structure

Transcript identifiers

Ensembl transcripts: 49 — 42 protein_coding, 5 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000263710, ENST00000409078, ENST00000418989, ENST00000430234, ENST00000449975, ENST00000452274, ENST00000455322, ENST00000463621, ENST00000472776, ENST00000474065, ENST00000480007, ENST00000485112, ENST00000491646, ENST00000541377, ENST00000696935, ENST00000700754, ENST00000700755, ENST00000877407, ENST00000877408, ENST00000961907, ENST00000961908, ENST00000961909, ENST00000961910, ENST00000961911, ENST00000961912, ENST00000961913, ENST00000961914, ENST00000961915, ENST00000961916, ENST00000961917, ENST00000961918, ENST00000961919, ENST00000961920, ENST00000961921, ENST00000961922, ENST00000961923, ENST00000961924, ENST00000961925, ENST00000961926, ENST00000961927, ENST00000961928, ENST00000961929, ENST00000961930, ENST00000961931, ENST00000961932, ENST00000961933, ENST00000961934, ENST00000961935, ENST00000961936

RefSeq mRNA: 8 — MANE Select: NM_001395891 NM_001142273, NM_001142274, NM_001207051, NM_001378003, NM_001378004, NM_001378005, NM_001395891, NM_015282

CCDS: CCDS92851, CCDS92852, CCDS92853, CCDS92854

Canonical transcript exons

ENST00000696935 — 41 exons

Exon	Start	End
ENSE00000857213	121448276	121448325
ENSE00000963879	121530247	121530325
ENSE00001020860	121427404	121427430
ENSE00001275221	121448953	121449120
ENSE00001275227	121450913	121450990
ENSE00001341077	121605701	121606180
ENSE00001363713	121430073	121430177
ENSE00001363830	121447337	121447507
ENSE00001363849	121451790	121451849
ENSE00001363854	121457687	121457757
ENSE00001584912	121649372	121649462
ENSE00001614542	121337776	121340947
ENSE00002363734	121404371	121404434
ENSE00002370767	121458840	121458975
ENSE00002407519	121407471	121407715
ENSE00002444616	121401868	121401870
ENSE00003463416	121363172	121363300
ENSE00003469214	121387763	121387906
ENSE00003514732	121348512	121348718
ENSE00003539726	121347038	121347154
ENSE00003551470	121515665	121515762
ENSE00003563240	121462532	121462605
ENSE00003574373	121398322	121398400
ENSE00003582522	121469808	121469960
ENSE00003586143	121461101	121461193
ENSE00003589059	121365094	121365284
ENSE00003609948	121527799	121527890
ENSE00003612658	121387122	121387228
ENSE00003617302	121459980	121460125
ENSE00003625020	121377499	121377649
ENSE00003625435	121503167	121503234
ENSE00003634691	121525845	121525920
ENSE00003634998	121401509	121401672
ENSE00003639293	121528677	121528780
ENSE00003673163	121397140	121397283
ENSE00003688769	121367588	121367831
ENSE00003756210	121410866	121410969
ENSE00003757808	121425139	121425306
ENSE00003968979	121382208	121382324
ENSE00003968980	121418622	121418729
ENSE00003968981	121414141	121414203

Expression profiles

Bgee: expression breadth ubiquitous, 286 present calls, max score 96.66.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 28.1157 / max 1411.1280, expressed in 1820 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
30463	20.3271	1799
30460	4.1596	1417
30464	1.0720	680
30458	0.8142	483
30452	0.6678	117
30451	0.6188	113
30449	0.2182	76
30459	0.1915	60
30454	0.0305	15
30457	0.0083	3

Top tissues by expression

298 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	96.66	gold quality
calcaneal tendon	UBERON:0003701	95.65	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	95.54	gold quality
adrenal tissue	UBERON:0018303	95.49	gold quality
dorsal root ganglion	UBERON:0000044	95.04	gold quality
CA1 field of hippocampus	UBERON:0003881	95.01	gold quality
postcentral gyrus	UBERON:0002581	94.77	gold quality
cerebellar vermis	UBERON:0004720	94.72	gold quality
corpus callosum	UBERON:0002336	94.70	gold quality
parietal lobe	UBERON:0001872	94.64	gold quality
inferior olivary complex	UBERON:0002127	93.88	gold quality
lateral nuclear group of thalamus	UBERON:0002736	93.58	gold quality
entorhinal cortex	UBERON:0002728	93.57	gold quality
superior vestibular nucleus	UBERON:0007227	93.29	gold quality
pons	UBERON:0000988	93.18	gold quality
superior frontal gyrus	UBERON:0002661	93.13	gold quality
ventral tegmental area	UBERON:0002691	93.08	gold quality
trigeminal ganglion	UBERON:0001675	93.00	gold quality
ganglionic eminence	UBERON:0004023	92.98	gold quality
medulla oblongata	UBERON:0001896	92.88	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	92.63	gold quality
sural nerve	UBERON:0015488	92.58	gold quality
renal medulla	UBERON:0000362	92.51	gold quality
substantia nigra pars compacta	UBERON:0001965	92.37	gold quality
substantia nigra pars reticulata	UBERON:0001966	92.33	gold quality
left ventricle myocardium	UBERON:0006566	92.08	gold quality
inferior vagus X ganglion	UBERON:0005363	91.95	gold quality
colonic epithelium	UBERON:0000397	91.93	gold quality
lateral globus pallidus	UBERON:0002476	91.79	gold quality
body of tongue	UBERON:0011876	91.69	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	48.94
E-ANND-3	yes	5.85

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): KAT5, ZHX2

miRNA regulators (miRDB)

126 targeting CLASP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-219A-5P	99.91	73.36	735

Functional genomics

ClinGen dosage: haploinsufficiency 0 (no evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 17)

• These results suggest that CLASP1 is required at kinetochores to regulate the dynamic behavior of attached microtubules. (PMID:14504462)
• propose that CLASP1 and CLASP2 can mediate interactions between microtubule plus ends and the cell cortex and act as local rescue factors, possibly through forming a complex with EB1 at microtubule tips (PMID:15631994)
• A fusion protein of the putative microtubule-binding domain (1-662 out of 1289 residues) of hOrbit1 & GFP was transfected into human cells. The GFP-hOrbit1 N-terminal fragment binds to the newly formed microtubules rather than the pre-formed ones. (PMID:16145243)
• CLASPs provide apparent stabilization of microtubules by locally reducing the amplitude of growth/shortening episodes at the microtubule ends. (PMID:16866869)
• Data propose that PRC1 forms a link between stabilization of CLASP1 association with central spindle microtubules and anti-parallel microtubule elongation. (PMID:19561070)
• A role for microtubules that form at the Golgi membranes is identified in a manner dependent on the microtubule regulators CLASPs. (PMID:19701196)
• Data show that CLASP1-astrin-Kif2b complex acts as a central switch at kinetochores that defines mitotic progression and promotes fidelity by temporally regulating kinetochore-microtuble attachments. (PMID:20852589)
• Data show that the tau-related protein MAP4 and the microtubule rescue factor CLASP1 are essential for maintaining spindle position and the correct cell-division axis. (PMID:21822276)
• Data show that CENP-E-mediated traction forces on misaligned chromosomes are responsible for the irreversible loss of spindle-pole integrity in CLASP1/2-depleted cells. (PMID:22307330)
• Acute silencing of CLASP1, a +TIP that participates in microtubule stabilization at the cell periphery, impairs trypomastigote internalization without diminishing the capacity for calcium-regulated lysosome exocytosis. (PMID:23107073)
• findings highlight the common mechanistic use of TOG domains in XMAP215 and CLASP families to regulate MT dynamics and suggest that differential TOG domain architecture may confer distinct functions to these critical cytoskeletal regulators (PMID:23727231)
• our data suggest a model for mitotic spindle positioning in which RanGTP and CLASP1 cooperate to align the spindle along the long axis of the dividing cell. (PMID:23783028)
• The epiblast epithelial status was maintained by anchoring microtubules to the basal cortex via CLIP1, a microtubule plus-end tracking protein, and Dystroglycan, a transmembrane protein that bridges the cytoskeleton and basement membrane (BM). (PMID:23940118)
• Propose that CLASPs couple microtubule organization, vesicle transport and cell interactions with the ECM, establishing a local secretion pathway that facilitates focal adhesion turnover by severing cell-matrix connections. (PMID:24859005)
• Prickle1 localized to the membrane through its farnesyl moiety, and the membrane localization was necessary for Prickle1 to regulate migration, to bind to CLASPs and LL5beta, and to promote microtubule targeting of focal adhesions. (PMID:27378169)
• catastrophe inhibition by SLAIN2 and CLASP1 supports mesenchymal cell shape in soft 3D matrices by enabling microtubules to perform a load-bearing function. (PMID:27939686)
• Differential regulation of single microtubules and bundles by a three-protein module. (PMID:34083810)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio		ENSDARG00000104358
danio_rerio		ENSDARG00000115906
mus_musculus	Clasp1	ENSMUSG00000064302
rattus_norvegicus	Clasp1	ENSRNOG00000002376

Paralogs (3): CLASP2 (ENSG00000163539), TOGARAM2 (ENSG00000189350), TOGARAM1 (ENSG00000198718)

Protein

Protein identifiers

CLIP-associating protein 1 — Q7Z460 (reviewed: Q7Z460)

Alternative names: Cytoplasmic linker-associated protein 1, Multiple asters homolog 1, Protein Orbit homolog 1

All UniProt accessions (8): Q7Z460, A0A8V8TLP7, A0A8V8TQK9, A0A8V8TRF6, C9J151, C9JP76, F8WA11, H0Y5T1

UniProt curated annotations — full annotation on UniProt →

Function. Microtubule plus-end tracking protein that promotes the stabilization of dynamic microtubules. Involved in the nucleation of noncentrosomal microtubules originating from the trans-Golgi network (TGN). Required for the polarization of the cytoplasmic microtubule arrays in migrating cells towards the leading edge of the cell. May act at the cell cortex to enhance the frequency of rescue of depolymerizing microtubules by attaching their plus-ends to cortical platforms composed of ERC1 and PHLDB2. This cortical microtubule stabilizing activity is regulated at least in part by phosphatidylinositol 3-kinase signaling. Also performs a similar stabilizing function at the kinetochore which is essential for the bipolar alignment of chromosomes on the mitotic spindle.

Subunit / interactions. Interacts with CLIP2, ERC1, MAPRE1, MAPRE3, microtubules, PHLDB2 and RSN. The interaction with ERC1 may be mediated by PHLDB2. Interacts with GCC2; recruits CLASP1 to Golgi membranes. Interacts with MACF1. Interacts with mtcl2 and MTCL1.

Subcellular location. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome. Chromosome. Centromere. Kinetochore. Spindle. Golgi apparatus. trans-Golgi network.

Similarity. Belongs to the CLASP family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q7Z460-1	1	yes
Q7Z460-2	2
Q7Z460-3	3
Q7Z460-4	4
Q7Z460-5	5

RefSeq proteins (8): NP_001135745, NP_001135746, NP_001193980, NP_001364932, NP_001364933, NP_001364934, NP_001382820, NP_056097 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011989	ARM-like	Homologous_superfamily
IPR016024	ARM-type_fold	Homologous_superfamily
IPR021133	HEAT_type_2	Repeat
IPR024395	CLASP_N_dom	Domain
IPR034085	TOG	Domain
IPR048491	XMAP215_CLASP_TOG	Domain
IPR057546	HEAT_GCN1	Domain

Pfam: PF12348, PF21040, PF21041, PF23271

UniProt features (104 total): helix 34, modified residue 27, compositionally biased region 10, region of interest 9, splice variant 8, repeat 7, turn 3, sequence conflict 2, chain 1, coiled-coil region 1, sequence variant 1, strand 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
6MQ7	X-RAY DIFFRACTION	1.78
4K92	X-RAY DIFFRACTION	2
6MQ5	X-RAY DIFFRACTION	2.15

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7Z460-F1	69.44	0.45

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (27): 246, 545, 548, 558, 559, 568, 600, 636, 646, 647, 649, 656, 684, 688, 695, 705, 711, 714, 787, 797 …

Function

Pathways and Gene Ontology

Reactome pathways

14 pathways

ID	Pathway
R-HSA-141444	Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
R-HSA-2467813	Separation of Sister Chromatids
R-HSA-2500257	Resolution of Sister Chromatid Cohesion
R-HSA-2565942	Regulation of PLK1 Activity at G2/M Transition
R-HSA-380259	Loss of Nlp from mitotic centrosomes
R-HSA-380270	Recruitment of mitotic centrosome proteins and complexes
R-HSA-380284	Loss of proteins required for interphase microtubule organization from the centrosome
R-HSA-380320	Recruitment of NuMA to mitotic centrosomes
R-HSA-428890	Role of ABL in ROBO-SLIT signaling
R-HSA-5620912	Anchoring of the basal body to the plasma membrane
R-HSA-5663220	RHO GTPases Activate Formins
R-HSA-68877	Mitotic Prometaphase
R-HSA-8854518	AURKA Activation by TPX2
R-HSA-9648025	EML4 and NUDC in mitotic spindle formation

MSigDB gene sets: 564 (showing top): GSE45365_NK_CELL_VS_CD8_TCELL_DN, GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, GOBP_CHROMOSOME_ORGANIZATION, GOBP_ESTABLISHMENT_OF_SPINDLE_ORIENTATION, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_REGULATION_OF_PROTEIN_POLYMERIZATION, GOBP_CYTOPLASMIC_MICROTUBULE_ORGANIZATION, TAATAAT_MIR126, GOBP_ACTIN_FILAMENT_BUNDLE_ORGANIZATION, MYOGENIN_Q6, GOBP_ESTABLISHMENT_OR_MAINTENANCE_OF_CELL_POLARITY, GOBP_REGULATION_OF_MICROTUBULE_BASED_PROCESS, GOBP_REGULATION_OF_WOUND_HEALING, GOBP_VESICLE_LOCALIZATION, GOBP_MICROTUBULE_ANCHORING

GO Biological Process (30): microtubule cytoskeleton organization (GO:0000226), microtubule bundle formation (GO:0001578), obsolete vesicle targeting (GO:0006903), microtubule nucleation (GO:0007020), negative regulation of microtubule depolymerization (GO:0007026), Golgi organization (GO:0007030), mitotic spindle organization (GO:0007052), establishment or maintenance of cell polarity (GO:0007163), exit from mitosis (GO:0010458), positive regulation of epithelial cell migration (GO:0010634), astral microtubule organization (GO:0030953), microtubule organizing center organization (GO:0031023), negative regulation of microtubule polymerization or depolymerization (GO:0031111), positive regulation of microtubule polymerization (GO:0031116), microtubule anchoring (GO:0034453), establishment of mitotic spindle localization (GO:0040001), positive regulation of exocytosis (GO:0045921), establishment of spindle orientation (GO:0051294), cell division (GO:0051301), negative regulation of stress fiber assembly (GO:0051497), regulation of focal adhesion assembly (GO:0051893), basement membrane organization (GO:0071711), positive regulation of extracellular matrix disassembly (GO:0090091), mitotic spindle assembly (GO:0090307), negative regulation of wound healing, spreading of epidermal cells (GO:1903690), regulation of gastrulation (GO:0010470), regulation of epithelial to mesenchymal transition (GO:0010717), establishment of cell polarity (GO:0030010), regulation of microtubule polymerization or depolymerization (GO:0031110), obsolete positive regulation of basement membrane assembly involved in embryonic body morphogenesis (GO:1904261)

GO Molecular Function (6): dystroglycan binding (GO:0002162), microtubule binding (GO:0008017), kinetochore binding (GO:0043515), microtubule plus-end binding (GO:0051010), protein binding (GO:0005515), tubulin binding (GO:0015631)

GO Cellular Component (22): kinetochore (GO:0000776), Golgi apparatus (GO:0005794), centrosome (GO:0005813), microtubule organizing center (GO:0005815), kinetochore microtubule (GO:0005828), cytosol (GO:0005829), spindle microtubule (GO:0005876), cytoplasmic microtubule (GO:0005881), cell cortex (GO:0005938), membrane (GO:0016020), cortical microtubule cytoskeleton (GO:0030981), centrosomal corona (GO:0031592), microtubule plus-end (GO:0035371), basal cortex (GO:0045180), mitotic spindle (GO:0072686), chromosome, centromeric region (GO:0000775), chromosome (GO:0005694), cytoplasm (GO:0005737), spindle (GO:0005819), cytoskeleton (GO:0005856), microtubule (GO:0005874), focal adhesion (GO:0005925)

Reactome top-level categories

Rollup of top-10 pathways:

Category	Pathways
Mitotic Prometaphase	3
G2/M Transition	2
Centrosome maturation	2
Amplification of signal from the kinetochores	1
Mitotic Anaphase	1
Loss of proteins required for interphase microtubule organization from the centrosome	1
Signaling by ROBO receptors	1
Assembly of the 9+0 primary cilium	1
RHO GTPase Effectors	1
M Phase	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
microtubule cytoskeleton organization	4
intracellular membraneless organelle	4
cytoplasm	4
microtubule cytoskeleton	3
microtubule-based process	2
microtubule polymerization	2
mitotic cell cycle	2
spindle organization	2
microtubule cytoskeleton organization involved in mitosis	2
cellular process	2
establishment of spindle localization	2
binding	2
spindle	2
microtubule	2
cytoskeleton organization	1
microtubule depolymerization	1
negative regulation of microtubule polymerization or depolymerization	1
regulation of microtubule depolymerization	1
negative regulation of protein depolymerization	1
negative regulation of supramolecular fiber organization	1
organelle organization	1
endomembrane system organization	1
mitotic cell cycle phase transition	1
mitotic nuclear division	1
epithelial cell migration	1
regulation of epithelial cell migration	1
positive regulation of cell migration	1
cytoplasmic microtubule organization	1
cellular component organization	1
microtubule polymerization or depolymerization	1
regulation of microtubule polymerization or depolymerization	1
negative regulation of cytoskeleton organization	1
positive regulation of microtubule polymerization or depolymerization	1
regulation of microtubule polymerization	1
positive regulation of protein polymerization	1
positive regulation of supramolecular fiber organization	1
exocytosis	1
regulation of exocytosis	1
positive regulation of secretion by cell	1

Protein interactions and networks

STRING

1344 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CLASP1	CLASRP	Q8N2M8	958
CLASP1	CLIP1	P30622	954
CLASP1	CLIP2	Q9UDT6	912
CLASP1	KIF2B	Q8N4N8	901
CLASP1	SPAG5	Q96R06	740
CLASP1	CENPE	Q02224	688
CLASP1	MAPRE3	Q9UPY8	635
CLASP1	KNSTRN	Q9Y448	630
CLASP1	PHLDB2	Q86SQ0	597
CLASP1	KIF18A	Q8NI77	557
CLASP1	SLAIN2	Q9P270	554
CLASP1	DCTN1	Q14203	521
CLASP1	KIF2C	Q99661	519
CLASP1	INCENP	Q9NQS7	510
CLASP1	GSK3B	P49841	507

IntAct

148 interactions, top by confidence:

A	B	Type	Score
YWHAG	CLASP1	psi-mi:“MI:0915”(physical association)	0.900
YWHAQ	WDR62	psi-mi:“MI:0914”(association)	0.830
YWHAH	ABLIM1	psi-mi:“MI:0914”(association)	0.800
CLASP1	YWHAE	psi-mi:“MI:0915”(physical association)	0.650
YWHAG	BLTP3B	psi-mi:“MI:2364”(proximity)	0.640
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610
YWHAB	BLTP3B	psi-mi:“MI:2364”(proximity)	0.610
YWHAB	BLTP3B	psi-mi:“MI:0914”(association)	0.610
YWHAH	BLTP3B	psi-mi:“MI:2364”(proximity)	0.570
YWHAG	SHTN1	psi-mi:“MI:0914”(association)	0.560
CLASP1	KIF1B	psi-mi:“MI:0914”(association)	0.560
CLASP1	KIF1B	psi-mi:“MI:0915”(physical association)	0.560
CLASP1	SPAG5	psi-mi:“MI:0915”(physical association)	0.560
YWHAQ	IGLC7	psi-mi:“MI:0914”(association)	0.530
YWHAB	SHTN1	psi-mi:“MI:0914”(association)	0.530
YWHAE	SHTN1	psi-mi:“MI:0914”(association)	0.530
MIS12	SPC24	psi-mi:“MI:0914”(association)	0.530
YWHAZ	BLTP3B	psi-mi:“MI:0914”(association)	0.530
BSG	BTAF1	psi-mi:“MI:0914”(association)	0.530
LPAR1	TMEM223	psi-mi:“MI:0914”(association)	0.530
PNMA2	CCDC85C	psi-mi:“MI:0914”(association)	0.530
CLASP1	Clip2	psi-mi:“MI:0915”(physical association)	0.520
Clip1	CLASP1	psi-mi:“MI:0915”(physical association)	0.510
CLASP1	Clip1	psi-mi:“MI:0915”(physical association)	0.510
YWHAB	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
YWHAQ	PLEKHG3	psi-mi:“MI:0914”(association)	0.480

BioGRID (194): CLASP1 (Two-hybrid), CLASP1 (Reconstituted Complex), GCC2 (Co-fractionation), CLASP1 (Affinity Capture-MS), CLIP2 (Affinity Capture-Western), CLASP1 (Affinity Capture-Western), CLASP1 (Proximity Label-MS), CLASP1 (Biochemical Activity), CLASP1 (Proximity Label-MS), CLASP1 (Proximity Label-MS), CLASP1 (Proximity Label-MS), CLASP1 (Proximity Label-MS), CLASP1 (Proximity Label-MS), CLASP1 (Affinity Capture-MS), CLASP1 (Affinity Capture-MS)

ESM2 similar proteins: A0A3Q1LSX9, A1A5G0, A1A5K2, A2A5R2, A2APV2, A2VE70, D3ZYR1, O00203, O04376, O35643, O60308, O75122, P52303, Q05397, Q08AM6, Q08DS7, Q0JRZ9, Q10567, Q13367, Q28FH2, Q32PG1, Q3UQN2, Q4U0G1, Q561M0, Q5R807, Q5ZIW5, Q6NUP7, Q6NXC0, Q6NYW6, Q6ZPF4, Q7TSU1, Q7YRF1, Q7Z460, Q80TV8, Q8BRT1, Q8C0Y0, Q8IVF7, Q8LF36, Q8N7B6, Q8RW96

Diamond homologs: A1A5G0, A1A5K2, O75122, Q4U0G1, Q61J98, Q61QN4, Q6NYW6, Q7Z460, Q80TV8, Q8BRT1, Q99JD4, Q9NBD7, Q9PT63, Q03609, Q61KX5, P32744, Q95YF0, A2AGT5, O94534, Q14008, Q1ZXQ8, Q9VEZ3

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
TPX2	“up-regulates activity”	CLASP1	binding
CLASP1	“up-regulates activity”	CLIP1	binding
CLASP1	“up-regulates activity”	CLIP2	binding
CLASP1	“up-regulates activity”	MAPRE1	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 147 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	7	59.9×	8e-10
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	7	52.8×	2e-09
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	7	52.8×	2e-09
Activation of BH3-only proteins	7	39.0×	1e-08
RHO GTPases activate PKNs	7	24.9×	2e-07
Intrinsic Pathway for Apoptosis	7	23.0×	4e-07
Translocation of SLC2A4 (GLUT4) to the plasma membrane	12	20.8×	9e-11
RHO GTPases activate IQGAPs	5	19.4×	6e-05

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of microtubule polymerization	5	27.9×	2e-04
protein targeting	5	15.1×	3e-03
non-motile cilium assembly	5	12.0×	7e-03
mitotic spindle organization	5	11.2×	8e-03
microtubule cytoskeleton organization	10	10.0×	3e-05
intracellular protein localization	10	8.7×	8e-05
mitotic cell cycle	7	7.7×	5e-03
cell division	15	5.7×	3e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

403 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	10
Likely pathogenic	9
Uncertain significance	286
Likely benign	22
Benign	13

Top pathogenic / likely-pathogenic (19)

Variant ID	HGVS	Classification
1341988	GRCh37/hg19 2q14.2-14.3(chr2:120628484-127658188)x1	Pathogenic
1808683	GRCh37/hg19 2q14.2-14.3(chr2:121241775-126487783)x1	Pathogenic
2498871	GRCh37/hg19 2q14.2(chr2:121981917-122363471)x1	Pathogenic
2813456	NC_000002.12:g.121531003G>T	Pathogenic
30179	NR_023343.3(RNU4ATAC):n.55G>A	Pathogenic
30181	NC_000002.12:g.121530990G>A	Pathogenic
4682547	GRCh37/hg19 2q14.2-14.3(chr2:120941682-124792343)x1	Pathogenic
636959	NR_023343.3(RNU4ATAC):n.46G>A	Pathogenic
977779	NR_023343.3(RNU4ATAC):n.120T>G	Pathogenic
977780	NR_023343.3(RNU4ATAC):n.114G>C	Pathogenic
1224468	NR_023343.3(RNU4ATAC):n.124delG	Likely pathogenic
30180	NR_023343.1:n.30G>A	Likely pathogenic
30182	NC_000002.12:g.121530929G>C	Likely pathogenic
3771898	NR_023343.3(RNU4ATAC):n.38A>T	Likely pathogenic
4699372	NR_023343.3(RNU4ATAC):n.33C>G	Likely pathogenic
692040	NM_001395891.1(CLASP1):c.196-562G>T	Likely pathogenic
812960	NC_000002.12:g.121530995A>T	Likely pathogenic
977856	NR_023343.3(RNU4ATAC):n.46G>T	Likely pathogenic
977869	NR_023343.3(RNU4ATAC):n.29T>G	Likely pathogenic

SpliceAI

12709 predictions. Top by Δscore:

Variant	Effect	Δscore
19:12847288:A:AG	acceptor_gain	1.0000
19:12847289:G:GA	acceptor_gain	1.0000
19:12847289:GT:G	acceptor_gain	1.0000
19:12847289:GTC:G	acceptor_gain	1.0000
19:12847289:GTCCT:G	acceptor_gain	1.0000
19:12847401:G:GT	donor_gain	1.0000
19:12847446:CTCAG:C	donor_loss	1.0000
19:12847447:TCAG:T	donor_loss	1.0000
19:12847448:CAG:C	donor_loss	1.0000
19:12847449:AGG:A	donor_loss	1.0000
19:12847451:G:GA	donor_loss	1.0000
19:12847452:T:A	donor_loss	1.0000
19:12847609:CA:C	acceptor_loss	1.0000
19:12847610:A:AG	acceptor_gain	1.0000
19:12847611:G:GA	acceptor_gain	1.0000
19:12847611:GC:G	acceptor_gain	1.0000
19:12847611:GCC:G	acceptor_gain	1.0000
19:12847611:GCCC:G	acceptor_gain	1.0000
19:12847611:GCCCC:G	acceptor_gain	1.0000
19:12847674:A:T	donor_gain	1.0000
19:12847843:CGCA:C	acceptor_loss	1.0000
19:12847844:GCA:G	acceptor_loss	1.0000
19:12847847:GGCC:G	acceptor_gain	1.0000
19:12848054:AGAC:A	donor_gain	1.0000
19:12848054:AGACG:A	donor_loss	1.0000
19:12848055:GAC:G	donor_gain	1.0000
19:12848055:GACG:G	donor_gain	1.0000
19:12848055:GACGT:G	donor_loss	1.0000
19:12848056:AC:A	donor_gain	1.0000
19:12848056:ACGTG:A	donor_loss	1.0000

AlphaMissense

10153 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:121340918:C:A	R1520S	1.000
2:121340918:C:G	R1520S	1.000
2:121340919:C:A	R1520M	1.000
2:121340937:A:G	L1514P	1.000
2:121340940:A:G	L1513P	1.000
2:121347051:A:G	L1506P	1.000
2:121347060:A:G	L1503P	1.000
2:121347072:A:G	L1499P	1.000
2:121347109:A:G	C1487R	1.000
2:121347110:A:C	F1486L	1.000
2:121347110:A:T	F1486L	1.000
2:121347112:A:G	F1486L	1.000
2:121347114:A:T	V1485E	1.000
2:121347116:G:C	S1484R	1.000
2:121347116:G:T	S1484R	1.000
2:121347118:T:G	S1484R	1.000
2:121347122:C:A	K1482N	1.000
2:121347122:C:G	K1482N	1.000
2:121347124:T:C	K1482E	1.000
2:121347126:C:G	R1481P	1.000
2:121347127:G:T	R1481S	1.000
2:121348600:G:T	A1442D	1.000
2:121348606:A:G	L1440P	1.000
2:121348645:A:G	L1427P	1.000
2:121348705:G:T	A1407D	1.000
2:121348706:C:G	A1407P	1.000
2:121363200:A:G	L1393P	1.000
2:121365116:A:G	L1352P	1.000
2:121365119:A:G	L1351P	1.000
2:121365122:A:G	L1350P	1.000

dbSNP variants (sampled 300 via entrez): RS1000004283 (2:121546749 G>A), RS1000006224 (2:121446975 G>A,T), RS1000010563 (2:121411685 A>C,G,T), RS1000011268 (2:121379143 A>G), RS1000014259 (2:121553841 G>A), RS1000033694 (2:121405431 G>A), RS1000071790 (2:121344953 T>C), RS1000099927 (2:121463766 T>C), RS1000118892 (2:121507816 A>G,T), RS1000122574 (2:121483587 C>G,T), RS1000146263 (2:121373264 T>C), RS1000150228 (2:121598703 T>C), RS1000151346 (2:121578489 GGAGGCC>G), RS1000152458 (2:121493156 A>C), RS1000154460 (2:121623355 G>A)

Disease associations

OMIM: gene MIM:605852 | disease phenotypes: MIM:210710, MIM:226960, MIM:300258, MIM:616651, MIM:183900, MIM:123100, MIM:236600

GenCC curated gene-disease

Disease	Classification	Inheritance
focal epilepsy	Limited	Autosomal dominant
complex neurodevelopmental disorder	No Known Disease Relationship	Autosomal dominant

Mondo (12): microcephalic osteodysplastic primordial dwarfism type I (MONDO:0008871), Lowry-Wood syndrome (MONDO:0009191), Roifman syndrome (MONDO:0014722), RNU4ATAC spectrum disorder (MONDO:0100558), spondyloepiphyseal dysplasia congenita (MONDO:0008471), microcephaly (MONDO:0001149), cardiomyopathy (MONDO:0004994), craniosynostosis (MONDO:0015469), retinal disorder (MONDO:0005283), hydrocephalus, nonsyndromic, autosomal recessive 1 (MONDO:0009360), focal epilepsy (MONDO:0005384), complex neurodevelopmental disorder (MONDO:0100038)

Orphanet (7): Lowry-Wood syndrome (Orphanet:1824), Microcephalic osteodysplastic primordial dwarfism types I and III (Orphanet:2636), Roifman syndrome (Orphanet:353298), Spondyloepiphyseal dysplasia congenita (Orphanet:94068), Craniosynostosis (Orphanet:1531), Rare cardiomyopathy (Orphanet:167848), Congenital hydrocephalus (Orphanet:2185)

HPO phenotypes

19 total (20 of 19 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000657	Oculomotor apraxia
HP:0001249	Intellectual disability
HP:0001250	Seizure
HP:0001263	Global developmental delay
HP:0001290	Generalized hypotonia
HP:0001320	Cerebellar vermis hypoplasia
HP:0001321	Cerebellar hypoplasia
HP:0001344	Absent speech
HP:0002078	Truncal ataxia
HP:0002119	Ventriculomegaly
HP:0002317	Unsteady gait
HP:0002365	Hypoplasia of the brainstem
HP:0002540	Inability to walk
HP:0003593	Infantile onset
HP:0004322	Short stature
HP:0007074	Thick corpus callosum
HP:0007165	Periventricular heterotopia
HP:0009879	Simplified gyral pattern
HP:0000252	Microcephaly

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST004049_10	Cough in response to angiotensin-converting enzyme inhibitor drugs	1.000000e-09
GCST004049_9	Cough in response to angiotensin-converting enzyme inhibitor drugs	1.000000e-07
GCST006030_2	Chloride levels	2.000000e-09
GCST006031_5	Potassium levels	2.000000e-13
GCST007281_1	HDL cholesterol x physical activity interaction (1df test)	8.000000e-09
GCST007282_13	HDL cholesterol x physical activity interaction (2df test)	4.000000e-07
GCST009391_1293	Metabolite levels	7.000000e-07
GCST010173_105	Triglyceride levels	8.000000e-09
GCST010204_113	Low density lipoprotein cholesterol levels	2.000000e-24

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0005325	response to angiotensin-converting enzyme inhibitor
EFO:0009283	potassium measurement
EFO:0003940	physical activity
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0007805	HDL cholesterol change measurement
EFO:0010549	xanthosine measurement
EFO:0004530	triglyceride measurement
EFO:0004611	low density lipoprotein cholesterol measurement

MeSH disease descriptors (8)

Descriptor	Name	Tree numbers
D009202	Cardiomyopathies	C14.280.238
D003398	Craniosynostoses	C05.116.099.370.894.232; C05.660.207.240; C05.660.906.364; C16.131.621.207.240; C16.131.621.906.364
D004828	Epilepsies, Partial	C10.228.140.490.360
D008831	Microcephaly	C05.660.207.620; C10.500.507.400.500; C16.131.621.207.620; C16.131.666.507.400.500
D012164	Retinal Diseases	C11.768
C537038	Lowry Wood syndrome (supp.)
C535866	Roifman syndrome (supp.)
C535788	Spondyloepiphyseal dysplasia, congenita (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724765 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs62151109	CLASP1		0.00	0

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression	3
Valproic Acid	decreases expression	2
GSK-J4	increases expression	1
FR900359	affects phosphorylation	1
dicrotophos	increases expression	1
2,4,6-tribromophenol	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	increases abundance, affects cotreatment, increases oxidation	1
bisphenol A	affects cotreatment, increases methylation	1
decabromobiphenyl ether	decreases expression	1
arsenite	affects binding, decreases reaction	1
butyraldehyde	decreases expression	1
tetrabromobisphenol A	decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
coumarin	affects phosphorylation	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
pentanal	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
2,3,5-(triglutathion-S-yl)hydroquinone	increases ADP-ribosylation	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
pentabrominated diphenyl ether 100	increases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
LDN 193189	affects cotreatment, increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Air Pollutants	affects cotreatment, increases abundance, increases oxidation	1
Arsenic	affects methylation	1
Caffeine	affects phosphorylation	1

ChEMBL screening assays

10 unique, capped per target: 10 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651121	Binding	Binding affinity to human CLASP1 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1M0	Abcam K-562 CLASP1 KO	Cancer cell line	Female
CVCL_D2IK	Abcam Raji CLASP1 KO	Cancer cell line	Male
CVCL_SJ13	HAP1 CLASP1 (-) 1	Cancer cell line	Male
CVCL_SJ14	HAP1 CLASP1 (-) 2	Cancer cell line	Male
CVCL_UQ32	Abcam Jurkat CLASP1 KO	Cancer cell line	Male

Clinical trials (associated diseases)

399 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00438451	PHASE4	COMPLETED	Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs
NCT00522418	PHASE4	TERMINATED	Study Comparing Best Medical Practice With or Without VNS Therapy in Pharmacoresistant Partial Epilepsy Patients
NCT00855738	PHASE4	COMPLETED	A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice
NCT00955357	PHASE4	COMPLETED	Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures
NCT01190098	PHASE4	COMPLETED	Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy
NCT01235403	PHASE4	COMPLETED	Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure
NCT02208492	PHASE4	COMPLETED	The Effects on Cognitive Function of Levetiracetam (Keppra®) Compared to Carbamazepine (Tegretol®, Carmazepine®) as Monotherapy for Children With Partial Seizure; A Multicentric Randomized Controlled Study
NCT03607851	PHASE4	COMPLETED	Efficacy and Safety of Rapid Titration Protocols of Lacosamide
NCT05748236	PHASE4	UNKNOWN	The Efficacy and Safety of Lamotrigine Versus Carbamazepine in Focal Epilepsy
NCT07193277	PHASE4	RECRUITING	Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy
NCT00348530	PHASE4	UNKNOWN	Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy
NCT00371891	PHASE4	COMPLETED	Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS)
NCT00401856	PHASE4	COMPLETED	CMR to Assess Fibrosis in Cardiomyopathy Using Eplerenone
NCT00559338	PHASE4	COMPLETED	Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department
NCT00606775	PHASE4	UNKNOWN	The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy
NCT00658203	PHASE4	COMPLETED	Clinical Evaluation on Advanced Resynchronization
NCT00701220	PHASE4	COMPLETED	Statin Therapy for Ischemic and Nonischemic Cardiomyopathy
NCT00800761	PHASE4	COMPLETED	Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major
NCT00806390	PHASE4	TERMINATED	Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol
NCT01006473	PHASE4	COMPLETED	Exercise Training in Chagas Cardiomyopathy
NCT01261065	PHASE4	COMPLETED	Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure
NCT01345188	PHASE4	COMPLETED	Ranolazine in Ischemic Cardiomyopathy
NCT01868841	PHASE4	COMPLETED	123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging on a Small Field of View-High Efficiency Cardiac SPECT System
NCT02640846	PHASE4	UNKNOWN	Effects of Levosimendan, Milrinone and Norepinephrine on Left and Right Ventricular Function in Septic Shock
NCT03228823	PHASE4	UNKNOWN	Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS)
NCT04323852	PHASE4	COMPLETED	Can Vitamin D Reduce Heart Muscle Damage After Bypass Surgery?
NCT05034432	PHASE4	RECRUITING	The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients
NCT05718128	PHASE4	RECRUITING	Clinical Study of Endocardial Myocardial Biopsy
NCT06964464	PHASE4	RECRUITING	Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
NCT00391534	PHASE3	TERMINATED	EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy
NCT00522275	PHASE3	COMPLETED	Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
NCT00655486	PHASE3	COMPLETED	Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures
NCT00655551	PHASE3	COMPLETED	Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures
NCT00908349	PHASE3	COMPLETED	Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy
NCT00957047	PHASE3	COMPLETED	Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy
NCT00957372	PHASE3	COMPLETED	Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy
NCT00957684	PHASE3	COMPLETED	Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures
NCT00988429	PHASE3	COMPLETED	Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures
NCT02076698	PHASE3	COMPLETED	Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy
NCT02535091	PHASE3	COMPLETED	Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures